Buy Aurobindo Pharma With Target Of Rs 980: Motilal Oswal

Date:

Motilal Oswal has recommended a BUY on Aurobindo Pharma with a Target Price of Rs. 980, and an upside of 17% from CMP of Rs. 839.

Advertisement

Aurobindo Pharma (ARBP) delivered better-than-expected EBITDA, led by a) strong off-take in the ARV / Growth Market segment, b) revival in EU sales, c) steady ramp-up in US sales, and d) better gross margins (GM). Increased R&D spend, to some extent, affected profitability for the quarter.

We tweak our EPS estimate for ARBP for FY21/FY22, factoring in: a) a superior product mix, b) a higher spend on complex product development, and c) higher other income. We continue to value ARBP at 15x 12M forward earnings to arrive at TP of INR980. We remain positive on ARBP on the back of a) a robust ANDA pipeline, b) enhanced efforts toward developing as well as building manufacturing capacity for future products – comprising biosimilars, inhalers, transdermals, nasals, and injectables – for the developed markets, c) a steady base portfolio, and d) a healthy balance sheet. Reiterate Buy.

Buy Aurobindo pharma
Advertisement
Buy Aurobindo Pharma With Target Of Rs 980: Motilal Oswal 3

Advertisement

Above Stocks Teamhttps://www.abovestocks.com
Above Stocks Team is a hard-working team, which is lead by the founder and works on giving the latest and accurate information about the Indian Stock Market.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

Daily Analysis of Stock Market – NIFTY – 25th May 2022

On Tuesday, The market had a gap-up opening. Later,...

Daily Analysis of Stock Market – NIFTY – 24th May 2021

On Monday, The market had a gap up opening....

Daily Analysis of Stock Market – NIFTY – 21st May 2021

On Friday, The market had a gap up opening...

Daily Analysis of Stock Market – NIFTY – 20th May 2021

On Thursday, The market had a gap down opening....